Top Markets
Coin of the day
Daihan Pharmaceutical Co.,Ltd. Daihan Pharmaceutical Co.,Ltd.

Daihan Pharmaceutical Co.,Ltd.

023910
Rank in Stocks #21490
Operating from South Korea, Daihan Pharmaceutical Co.,Ltd. focuses on the... Operating from South Korea, Daihan Pharmaceutical Co.,Ltd. focuses on the development, manufacturing, and distribution of therapeutic medications. The company's diverse product portfolio features physician-prescribed drugs, over-the-counter (OTC) remedies, quasi-pharmaceuticals, and a variety of intravenous infusion solutions. Established in 1945, the firm's corporate headquarters are situated in Seoul, South Korea.
Share Price
$18.05
Last synced: 2026-08-21
Market Cap
$106.12M
Change (1 day)
-1.88%
Change (1 year)
-15.31%
Country
KR
Trade Daihan Pharmaceutical Co.,Ltd. (023910)

Category

P/E ratio for Daihan Pharmaceutical Co.,Ltd. (023910)
P/E ratio as of 2026 TTM: 0
According to Daihan Pharmaceutical Co.,Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Daihan Pharmaceutical Co.,Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.